🇺🇸 FDA
Pipeline program

Linaclotide

MCP-103-312

Approved small_molecule completed

Quick answer

Linaclotide for Irritable Bowel Syndrome Characterized by Constipation is a Approved program (small_molecule) at IRONWOOD PHARMACEUTICALS INC with 2 ClinicalTrials.gov record(s).

Program details

Company
IRONWOOD PHARMACEUTICALS INC
Indication
Irritable Bowel Syndrome Characterized by Constipation
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials